Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey A Porter

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Cancer Letters|July 29, 2004
Microsatellite instability in esophageal adenocarcinomaSusan C Evans, Amy Gillis, Laurette Geldenhuys, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense geneChristie Barclay, Audrey W Li, Laurette Geldenhuys, et al.
Cancer|June 23, 2005
Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinomaAlan G Casson, Zuoyu Zheng, Susan C Evans, et al.
BMC Cancer|May 22, 2009
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastasesOliver F Bathe, Scott Ernst, Francis R Sutherland, et al.
Annals of Surgical Oncology|July 4, 2002
Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patientsJeffrey E Lee, Joseph Abdalla, Geoffrey A Porter, et al.
The Journal of Thoracic and Cardiovascular Surgery|April 30, 2004
Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer CentersGeoffrey A Porter, Scott B Cantor, Garrett L Walsh, et al.
Cancer|January 30, 2002
Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomasGeoffrey A Porter, Scott B Cantor, Syed A Ahmad, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|June 17, 2005
Ten years of breast screening in the Nova Scotia Breast Screening Program, 1991-2001. experience: use of an adaptable stereotactic device in the diagnosis of screening-detected abnormalitiesJudy S Caines, Gerald H Schaller, Sian E Iles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancerEva Grunfeld, Jim A Julian, Gregory Pond, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancer Letters|July 29, 2004
Microsatellite instability in esophageal adenocarcinomaSusan C Evans, Amy Gillis, Laurette Geldenhuys, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense geneChristie Barclay, Audrey W Li, Laurette Geldenhuys, et al.
Cancer|June 23, 2005
Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinomaAlan G Casson, Zuoyu Zheng, Susan C Evans, et al.
BMC Cancer|May 22, 2009
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastasesOliver F Bathe, Scott Ernst, Francis R Sutherland, et al.
Annals of Surgical Oncology|July 4, 2002
Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patientsJeffrey E Lee, Joseph Abdalla, Geoffrey A Porter, et al.
The Journal of Thoracic and Cardiovascular Surgery|April 30, 2004
Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer CentersGeoffrey A Porter, Scott B Cantor, Garrett L Walsh, et al.
Cancer|January 30, 2002
Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomasGeoffrey A Porter, Scott B Cantor, Syed A Ahmad, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|June 17, 2005
Ten years of breast screening in the Nova Scotia Breast Screening Program, 1991-2001. experience: use of an adaptable stereotactic device in the diagnosis of screening-detected abnormalitiesJudy S Caines, Gerald H Schaller, Sian E Iles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancerEva Grunfeld, Jim A Julian, Gregory Pond, et al.
Pageof 4